Eiling Tech’s LiverScan drives precise diagnostics via real-time imaging

The tool offers quantifiable data for fibrosis and fatty liver levels.

ALL for the sake of liver health, Hong Kong-based Eiling Technology Ltd. has focused on developing an advanced scanning tool that leverages elastography for precise diagnostics.

Distinct from the traditional ultrasound, the company’s LiverScan device offers quantifiable and objective data to diagnose liver fibrosis and fatty liver levels.

Eiling Tech Project Director Alyssa Lin flaunted the device’s real-time imaging feature and underscored that whilst it is more advanced and even portable, the unit is affordable.

“Aside from specialised departments, we aim to bring professional diagnosis to the community with more clinics and small businesses providing these assessments,” Lin told Healthcare Asia in an exclusive interview. “We highly recommend that all of the citizens pay more attention to liver health as early as possible so that we can avoid severe diseases.”

A need for awareness

Despite their tech’s advantage in features, Lin acknowledged a significant barrier to market adoption: the general lack of awareness about elastography compared to conventional ultrasound techniques.

“Many of our physicians know about BMO (Bruch’s membrane opening) ultrasound since it is widely used in different protocols such as lower abdomen testing. But elastography is a different technique because it provides quantified results based on some algorithms and calculations,” she explained.

The public is not as well informed on this newer technology, noted Lin as she cited a need for efforts to stoke widespread awareness.

“It may take some time to educate or maybe to let people know about this professional exam, even though we would like to have all communities use our device,” she said.

Target: 1,000 units

Looking forward, Eiling Technology aims to deploy over 1,000 LiverScan units across Hong Kong within the year.

“We foresee more clinics and general practitioners (GPs) using this device so we expect multiple machines in the upcoming years,” Lin said.

She also told Healthcare Asia about plans for future collaborations with government bodies to further promote liver health awareness and screening programmes across the city.

At present, the diagnostic tool has been certified by the Food and Drug Administration (FDA) and is being utilised in private hospitals and community centres for diagnosis and volunteer screening programmes.

“Even small businesses and clinics can own the device to provide a more quantified liver diagnosis to patients and expand their markets compared to their traditional body-check items,” Lin said.